+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cell lysate, Primary antibody: P10596(STIP1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10596(STIP1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10596(STIP1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The STIP1 (Stress-Induced Phosphoprotein 1) antibody targets a multifunctional chaperone protein critical in cellular stress responses and protein homeostasis. STIP1. also known as HOP or STI1. contains tetratricopeptide repeat (TPR) domains that mediate interactions with heat shock proteins HSP70 and HSP90. facilitating client protein folding and stability. It plays a dual role as a co-chaperone, coordinating the transfer of substrates between HSP70 and HSP90. and as a signaling molecule influencing cell proliferation, apoptosis, and stress adaptation.

STIP1 is overexpressed in various cancers, including breast, liver, and glioblastoma, where it promotes tumor growth, metastasis, and therapy resistance by enhancing oncogenic signaling pathways (e.g., AKT, ERK) and inhibiting apoptosis. It also interacts with prion proteins in neurological contexts, potentially contributing to neurodegenerative diseases like Alzheimer’s.

Antibodies against STIP1 are essential tools for studying its expression, localization, and interactions in disease models. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to explore STIP1’s role in cancer progression, neuropathology, and stress response mechanisms. These antibodies also hold diagnostic potential, as elevated STIP1 levels in bodily fluids correlate with disease severity, offering prospects for biomarker development. Research continues to investigate STIP1-targeted therapies to modulate its chaperone activity or disrupt pathogenic interactions.